Curosurf/Budesonide for Infants With Respiratory Distress Syndrome
- Registration Number
- NCT02013115
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Brief Summary
Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- Clinical diagnosis of respiratory distress syndrome
- pneumothorax
- surgical disease
- major congenical defects
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cursurf and Budesonide Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
- Primary Outcome Measures
Name Time Method need of pulmonary surfactant one month The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant
- Secondary Outcome Measures
Name Time Method the incidence of bronchopulmonary dysplasia gestional age 36 weeks or later the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia.
Trial Locations
- Locations (1)
Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University
🇨🇳Chongqing, Chongqing, China